Glucose concentrations in blood and tissue – A pilot study on variable time lag

Biomedical Papers

Volumn 159, Issue 4, 2015, Pages 527-534

  Chlup, Rudolf ^a,b   Krejci, Jan ^c   O’Connell, Mark ^d   Sebestova, Blanka ^c   Plicka, Robert ^c   Jezova, Lucie ^c   Brozova, Tereza ^c,e   Doubravova, Blanka ^b,c   Zalesakova, Hana ^b,c   Durajkova, Emilia ^b,c   Vojtek, Jiri ^c   Bartek, Josef ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b Institute of Neurology and Geriatrics   (Czech Republic)

^c Institute of Neurology and Geriatrics ^*  (Czech Republic)

^d Probe Scientific Ltd   (United Kingdom)

^e BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

Author keywords

Calibration; Continuous glucose monitoring; Diabetes mellitus; Glucose transport; Lag phase

Indexed keywords

GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE MONITORING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; SUBCUTANEOUS TISSUE; TIME FACTOR;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; MALE; PILOT PROJECTS; SUBCUTANEOUS TISSUE; TIME FACTORS;

EID: 84949682670     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2015.007     Document Type: Article

References (35)

1. Takahashi S, Uchino H, Shimizu T, Kanazawa A, Tamura Y, Sakai K, Watada H, Hirose T, Kawamori R, Tanaka Y. Comparison of glycated albumin (GA) and gycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J 2007;54(1):139-44.
2. Dungan KM. 1,5-anhydroglucitol (GlycoMark™) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008;8(1):9-19.
3. Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther 2009;11(Suppl 1):S55-S65.
4. Kohnert K-D, Heinke P, Vogt L, Meyramov GG, Salzsieder E. Optimizing diabetes management: comprehensive analysis of glucose monitoring data and use of better metrics for glycemic control. Bulletin of the Karaganda University 2013;4(72):6-15.
5. Peterson K, Chlup R, Zapletalová J, Kohnert K, Kudlová P, Bartek J, Nakládalová M, Doubravová B, Sečkař P. Influence of oral antidiabet-ic drugs on hyperglycemic response to foods in persons with type 2 diabetes mellitus as assessed by continuous glucose monitoring system:a pilot study. J Diab Sci Tech 2010;4(4):983-92.
6. Chlup R, Doubravová B, Bartek J, Zapletalová J, Krystyník O, Procházka V. Effective assessment of diabetes control using personal glucometers (Contourlink, Bayer, Germany; Calla, Wellion, Austria; Linus, Agamatrix, USA). Disease Markers 2013;35(6):895-905.
7. Mlčák P, Fialová J, Trnková K, Chlup R. A continuous glucose monitoring system (CGMS) – a promising aproach for improving metabolic control in persons with type 1 diabetes mellitus treated by insulin pumps. Biomed Papers 2004;148(1):33-8.
8. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Bode B, Beck RW, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy KJ, Tamborlane WV, Weinzimer S, Wolpert H. Sustained benefit of continuous glucose monitoring on HbA1c, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care 2009;32(11):2047-9.
9. Cohen O, Körner A, Chlup R, Zoupas C, Rahozin A, Wudi K, Bartášková D, Pappas A, Niederland T, Taybani Z, Barák L, Vazeou AS. Improved glycemic control through continuous glucose sensor – augmented insulin pump therapy: Prospective results from a community and academic practice patient registry. J Diab Sci Techn 2009;3(4):804-11.
10. Peterson K, Zapletalová J, Kudlová P, Matušková V, Bartek J, Novotný D, Chlup R. Benefits of three-month continuous glucose monitoring for persons with diabetes using insulin pumps and sensors. Biomed Papers 2009;153(1):47-52.
11. Battelino T, Conget I, Olsen B, Schütz-Fuhrmann I, Hommel E, Hoogma R, Schierloh U, Sulli N, Bolinder J; SWITCH Study Group. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55:3155-62.
12. Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt MN. Short-and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care 2012;35(1):32-8.
13. Poljaková I, Elšíková E, Chlup R, Kalabus S, Hasala O, Zapletalová J. Glucose sensing module – is it time to integrate it into real-time perioperative monitoring? An observational pilot study with subcutaneous sensors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Rep 2013;157(4):346-57.
14. Chlup R, Jelenová D, Kudlová P, Chlupová K, Bartek J, Zapletalová J, Langová K, Chlupová L. Continuous glucose monitoring – novel approach to the determination of the glycaemic index of foods (DEGIF 1); Determination of the glycaemic index of foods by means of the CGMS. Exp Clin Endocrinol Diab 2006;144(12):68-74.
15. Chlup R, Peterson K, Zapletalová J, Kudlová P, Sečkař P. Extended prandial glycemic profiles of foods as assessed using continuous glucose monitoring enhance the power of the 120-minute glycemic index. J Diab Sci Tech 2010;4(3):615-24.
16. Rebrin K, Steil GM. Can Interstitial Glucose Assessment Replace Blood Glucose Measurements? Diabetes Technology & Therapeutics. October 2000;2(3):461-72. doi:10.1089/15209150050194332.
17. Thennadil SN, Rennert JL, Wenzel BJ, Hazen KH, Ruchti TL, Block MB. Comparison of glucose concentration in interstitial fluid, and capillary and venous blood during rapid changes in blood glucose levels. Diabetes Technology & Therapeutics. 2001;3(3):357-65. doi:10.1089/15209150152607132.
18. Boyne MS, Silver DM, Kaplan J, Saudek CD. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes 2003;52(11):2790-4. doi: 10.2337/diabetes.52.11.2790.
19. Hovorka R, Nodale M. Response to Mitre et al.: Analysis of Continuous Glucose Monitoring Data to Assess Outpatient Closed-Loop Studies: Considerations for Different Sensors. Diabetes Technology & Therapeutics 2014;16(5):328-9. doi:10.1089/dia.2013.0336.38.
20. Leelarathna L, Dellweg S, Mader JK, Allen JM, Benesch C, Doll W, Ellmerer M, Hartnell S, Heinemann L, Kojzar H, Michalewski L, Nodale M, Thabit H, Wilinska ME, Pieber TR, Arnolds S, Evans ML, Hovorka R; AP@home Consortium. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care 2014; 37(7):1931-7.
21. Bergenstal RM, Ahmann AJ, Bailey T, Beck RW, Bissen J, Buckingham B, Deeb L, Dolin RH, Garg SK, Goland R, Hirsch IB, Klonoff DC, Kruger DF, Matfin G, Mazze RS, Olson BA, Parkin C, Peters A, Powers MA, Rodriguez H, Southerland P, Strock ES, Tamborlane W, Wesley DM. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther 2013;15(3):198-211. doi: 10.1089/dia.2013.0051.
22. Chlup R, Krystynik O, Nadvornikova M, Zalesakova M, Durajkova E, Poljakova I, Kudlova P, Bartek J, Zapletalova J, Prochazka V. Benefits of advanced technologies for optimum therapy of type 1 and type 2 diabetes in practice. (Moderní technologie a způsob jejich využívání pro optimalizaci léčby diabetu 1. i 2. typu v praxi). Klin Farmakol Farmacie 2014;28(2):72-9.
23. Rodbard D. Clinical interpretation of indices of quality of glycemic control and glycemic variability. Postgrad Med 2011;123(4):107-18.
24. Salzsieder E, Vogt L, Heinke P, Augstein P. Q-score: a new tool for objective assessment and verification of the quality of continuously measured glucose profiles. Diabetologie und Stoffwechsel 2011;6:223.
25. Kohnert KD, Vogt L, Salzsieder E. Advances in understanding glucose variability and the role of continuous glucose monitoring. European Endocrinol 2010;6(1):53-56.
26. Fritzsche G, Kohnert KD, Heinke P, Vogt L, Salzsieder E. The use of a computer program to calculate the mean amplitude of glycemic excursions. Diabetes Technol Ther 2011;13(3):319-25.
27. Kohnert KD, Augstein P, Heinke P, Zander E, Peterson K, Freyse EJ, Salzsieder E. Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract 2007;77(3):420-6.
28. Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freyse EJ, Hovorka R, Salzsieder E. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009;32(6):1058-62.
29. Rawlings RA, Shi H, Yuan LH, Brehm W, Pop-Busui R, Nelson PW. Translating glucose variability metrics into the clinic via continuous glucose monitoring: a graphical user interface for diabetes evaluation (CGM-GUIDE©)// Diabetes Technol Ther 2011;13(12):1241-8.
30. Rutscher A, Salzsieder E, Thierbach U, Fischer U, Albrecht G. KADIS – a computer-aided decision support system for improving the management of type-I diabetes. Exp Clin Endocrinol 1990;95(1):137-47.
31. Augstein P, Vogt L, Kohnert KD, Freyse EJ, Heinke P, Salzsieder E. Outpatient assessment of Karlsburg Diabetes Management System-based decision support. Diabetes Care 2007;30(7):1704-8.
32. Salzsieder E, Vogt L, Kohnert KD, Heinke P, Augstein P. Model-based decision support in diabetes care. Comput Methods Prog Biomed 2011;102(2):206-18.
33. Rodbard D, Vigersky RA. Design of a decision support system to help clinicians manage glycemia in patients with type 2 diabetes mellitus. J Diabetes Sci Technol 2011;5(2):402-11.
34. Mastrototaro J, Welsh JB, Lee S. Practical considerations in the use of real-time continuous glucose monitoring alerts. J Diabetes Sci Technol 2010;4(3):733-9.
35. Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, Lee SW. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. The Lancet. Jul 2014 E pub ahead of print doi: 10.1016/S0140-6736(14)61037-0.